Big Pharma's Big Deals: A Sign of Strength or Desperation?
The pharmaceutical industry is in the midst of a frenzied M&A spree, with a record year for deals in sight. But are these mergers a sign of strength or weakness? Today, we dive into the world of drugs, politics, and deal-making.
Unhedged, the markets and finance podcast from the Financial Times and Pushkin, brings you this insightful discussion between Rob Armstrong, US finance commentator, and James Fontanella-Khan, US finance editor.
The Chilly Weather and the Hot M&A Scene
As the conversation begins, James, an Italian, shares his discomfort with the chilly New York weather. But the real heat is in the M&A market, where a wild wave of deals is unfolding. James admits his previous skepticism about the deal boom, but the industry is proving him wrong.
The Hunt for New Assets
The hosts explore the reasons behind the M&A frenzy. Big Pharma is on the prowl for new assets, as many large companies have reduced their R&D efforts. This has led to a shift towards smaller companies, which are often backed by VCs, to fill the innovation gap.
The Patent Game
The discussion turns to the patent system, a perennial driver of M&A activity. As older drugs go off-patent, companies must either develop new drugs in-house or acquire them from external sources. This has led to a competitive landscape where multiple Big Pharma companies vie for the same assets, driving up premiums.
The Cidara Deal: A Premium Story
The hosts delve into the remarkable story of the Cidara deal. Oliver Barnes, the M&A reporter, tipped them off about a potential acquisition, estimating the asset's value at $3 billion. However, the deal ended up going for a staggering $9 billion, with Merck as the buyer.
The Halda Deal and the Mother of All Crazy Deals
The conversation shifts to the Halda deal, a private company with a cancer drug that went for $3 billion. J&J outbid several other major players to secure the asset. But the real showstopper was the sale of Metsera, a biotech company with a revolutionary weight-loss drug.
The Pharma Industry's Changing Fortunes
The hosts reflect on the pharma industry's changing fortunes. Once a powerhouse, the industry has been underperforming the market for the past decade, with tech companies now occupying the top spot. This has left the pharma industry searching for its soul while tech dominates.
Mergers: Strength or Weakness?
James and Rob debate whether the recent mergers are a sign of strength or weakness. James argues that, in most cases, it's a sign of weakness, as companies are running out of options and need to replenish their pipelines. Many deals are defensive, aiming to secure drugs before rivals can.
The Metsera Deal: A Weighty Matter
The discussion turns to the Metsera deal, which is particularly intriguing due to its focus on weight loss, a hot area in pharma. Metsera's GLP-1 drug promises the same results as Ozempic with a single monthly dose, a significant innovation.
The Bidding War: Novo vs. Pfizer
The hosts explore the bidding war between Novo Nordisk and Pfizer for Metsera. Novo, the original weight-loss drug pioneer, faced competition from Pfizer, which struck a deal with Metsera in September. However, Novo made a higher bid in October, leading to a fierce battle.
Regulatory and Political Considerations
The conversation delves into the regulatory and political aspects of the deal. Pfizer, an American company, emphasized the deal's benefits to American consumers and regulators. This raised questions about whether Trump's presidency influenced the decision, favoring an American bidder over a European one.
The Role of CEOs and Political Connections
The hosts discuss the role of CEOs in these deals, highlighting Albert Bourla's (CEO of Pfizer) close relationship with President Trump. They also mention the pressure on pharma CEOs to address drug pricing, with Trump's administration taking a hard stance on the issue.
The Last Major Pharma Mergers and the Future
The hosts reflect on the last major wave of big pharma mergers in 2009 and wonder if the conditions are ripe for another round of big-to-big consolidation. James argues that the conditions have never been better, as executives are under pressure to lower drug prices, which could be achieved through M&A.
The AI Bubble and the Nasdaq's Future
The episode concludes with a speculative discussion about the AI bubble and the Nasdaq's future. James is long on the Nasdaq, believing it's a rare opportunity to buy the dip. Rob, on the other hand, is short, predicting a meaty correction by the end of the year.
Unhedged provides a fascinating insight into the complex world of pharma M&A, leaving listeners with plenty to ponder. Are these deals a sign of strength or desperation? And what does the future hold for the industry? Tune in to find out!
